Company profile: Eko
1.1 - Company Overview
Company description
- Provider of digital stethoscopes and an AI detection platform for heart and lung diseases, including CORE 500 with on-device ECG and heart rate display and Eko AI arrhythmia detection, 3M Littmann CORE, and the CORE Attachment with 40X amplification and noise cancellation, plus the Eko App to visualize, record, and share data; offers bulk group orders.
Products and services
- Arrhythmia Detection: AI-driven analysis that guides clinicians during exams to identify heart disease indicators, delivering AFib, tachycardia, and bradycardia detection within the Eko platform
- CORE 500™ Digital Stethoscope: ECG-integrated device that visualizes ECG and heart rate on-device, supports Eko AI arrhythmia detection, and operates up to 60 hours per charge with a durable build
- 3M™ Littmann® CORE Digital Stethoscope: Cardiology-grade instrument pairing Littmann hardware with Eko detection software to amplify sound clarity, cancel noise, and auscultate adult and pediatric patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eko
Ionetix
HQ: United States
Website
- Description: Provider of end-to-end radiopharmaceutical solutions for cardiac PET imaging, including N-13 Ammonia for myocardial perfusion; the ION-12SC compact superconducting cyclotron for on/near-campus N-13 production; Cardiac PET consultative services (layout, regulatory, camera/software, training); and targeted alpha therapy using Actinium-225 and Astatine-211 to target cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ionetix company profile →
TandemLife
HQ: United States
Website
- Description: Provider of innovative medical device products for cardiologists and cardiac surgeons worldwide, delivering unique solutions for patients requiring circulatory support, including the FDA-cleared TandemHeart System that provides extracorporeal circulatory support in minutes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TandemLife company profile →
Applied Therapeutics
HQ: United States
Website
- Description: Provider of drug development targeting molecules/pathways in fatal or debilitating diseases, with programs: govorestat for Galactosemia (pediatric Phase 3 completed; MAA validated; NDA accepted; PDUFA date set), SORD Deficiency (positive pilot; ongoing Phase 3), PMM2-CDG (Phase 2-ready; Expanded Access), AT-001 for Diabetic Cardiomyopathy/Peripheral Neuropathy (Phase 3), and AT-003 for Diabetic Retinopathy (Phase 1-ready).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied Therapeutics company profile →
Instylla
HQ: United States
Website
- Description: Provider of next-generation liquid embolics for interventional radiology. Offers the Embrace Hydrogel Embolic System (HES), a device that embolizes hypervascular tumors and peripheral arterial bleeds by forming a soft hydrogel to fill vessel lumens during embolization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instylla company profile →
CorFlow Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary medtech technologies to diagnose and treat microvascular obstructions (MVO) in heart attack patients. Offers the CoFI System for post-PCI coronary microcirculation assessment and controlled infusion of diagnostic/therapeutic agents, the CoFI Console acting as an infusion pump and displaying physiological parameters, an infusion-occlusion CoFI Catheter, and a single-use CoFI Cassette.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CorFlow Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eko
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eko
2.2 - Growth funds investing in similar companies to Eko
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eko
4.2 - Public trading comparable groups for Eko
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →